All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Keeping you up to date on recent developments in neurology, including: Light-based stimulation relieves symptoms of Parkinson's, Implant-free optogenetics minimizes brain damage during neuronal stimulation, Persistent and worsening insomnia may predict persistent depression in older adults.
The activity of many proteins is controlled through phosphorylation by kinases and dephosphorylation by phosphatases. Overactive kinases are one of the major drivers of tumors and, as a result, kinase inhibitors are a mainstay of oncology drug development. But “activation of the brakes, the phosphatases, could be equally therapeutically viable for the treatment of a broad range of cancers” to kinase inhibition, Goutham Narla told the audience at the 2020 American Association for Cancer Research (AACR) meeting.
Keeping you up to date on recent developments in diagnostics, including: Deep neural network for colorectal polyp classification; Biomarkers signal chemo-induced heart damage; AI helps gauge risk of severe COVID-19 infection; Platelets play role in Tylenol toxicity.
A multi-institutional group led by the University of California at San Francisco’s Quantitative Biosciences Institute (QBI) has identified more than 200 host proteins that interacted with SARS-CoV-2 viral proteins during infection, creating “a blueprint of how SARS-CoV-2 hijacks human cells,” QBI Director Nevan Krogan told reporters. They then used that blueprint to identify 10 drugs, some FDA approved and some in clinical trials, that were able to inhibit viral growth in cell culture assays, marking them for further study as potential antivirals. The work also identified one compound, dextromethorphan, that appeared to facilitate viral growth.
Keeping you up to date on recent developments in orthopedics, including: Physio support in COVID-19 recovery; Co-delivery of IL-10 and NT-3 to enhance spinal cord injury repair; European countries face a costly 23% increase in fragility fractures by 2030.
LONDON – Leading genome sequencing groups are launching the first meta-analysis in the hunt for genetic factors that explain why some people have worse COVID-19 symptoms than others, after agreeing to share patient sequence data from around the world.
Keeping you up to date on recent developments in oncology, including: Small tumors and large motion effects dampen treatment effect in IMPT; Pancreatic cancer uses autophagy to hide from immune system; NRF2 wakes sleeping tumor cells; Cancer renders patients more susceptible to COVID-19.
Keeping you up to date on recent developments in cardiology, including: Helping heart cells regenerate; Heart failure hormone has role in sepsis; Speeding up ER treatment; Cheating cell death improves infarct outcomes.
Keeping you up to date on recent developments in neurology, including: Nanocarrier developed for drug delivery across the BBB; 3D face analysis could screen for sleep apnea; Long noncoding RNA has sex-specific role in depression; Noncoding TET2 variants affect neurodegeneration risk.
BioWorld looks at translational medicine, including: Edited stem cells reverse mouse diabetes; Noncoding TET2 variants affect neurodegeneration risk; Pancreatic cancer uses autophagy to hide from immune system; Heart failure hormone has role in sepsis; NRF2 wakes sleeping tumor cells; Oral drug can wake up telomerase; Cheating cell death improves infarct outcomes; Older siblings’ example turns stem cells into heart cells; Lung changes from PD drug hopeful are reversible; Platelets play role in Tylenol toxicity.
RSS
